The mPEBv regimen (metronomic chemotherapy regimen with dose-fractioned cisplatin and oral etoposide (mPE) +/− bevacizumab) used in the respective study induced an anti-tumor immunization that could be enhanced by subsequent PD-1/PD-L1 checkpoint inhibitors [33]. The gene discussed is PDCD1; the disease is neoplasm.